Recruiting
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer - CA258-0001
Atualizado: 17 fevereiro, 2026 | ClinicalTrials.gov
Fase
Gênero(s)
Faixa etária
Localização(ões)
Recruiting
Inclusion Criteria - Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC). - Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines. - In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy. Exclusion Criteria - Participants must not have any untreated CNS metastases. - Participants must not have an active, known or suspected autoimmune disease. - Participants must not have had a prior organ or tissue allograft. - Other protocol-defined Inclusion/Exclusion criteria apply.
É altamente recomendável que você entre em contato com a BMS para relatar efeitos colaterais (eventos adversos).
Efeitos colaterais (eventos adversos) e outros eventos relatáveis estão definidos aqui.
Relate efeitos colaterais (eventos adversos) ou reclamações sobre a qualidade do produto: Informações médicas
